Compugen sees "encouraging signals" from early-stage cancer trial

Israeli cancer immunotherapy firm Compugen said on Monday it had positive initial results from an ongoing early-stage study of its COM701 therapy in patients with advanced solid tumours who have exhausted all standard treatments.